Manganese-based Prussian blue nanoparticles inhibit tumor proliferation and migration via the MAPK pathway in pancreatic cancer

Shanshi Tong\textsuperscript{1,2*}, Zhilong Yu\textsuperscript{3*}, Fang Yin\textsuperscript{4*}, Qilin Yang\textsuperscript{1}, Juhang Chu\textsuperscript{5}, Luyao Huang\textsuperscript{1}, Wenhao Gao\textsuperscript{6*} and Mingping Qian\textsuperscript{1,5*}

\textsuperscript{1}Department of General Surgery, Shanghai Tenth People’s Hospital, Shanghai, China, \textsuperscript{2}State Key Laboratory of Oncogenes and Related Genes, Renji Hospital, Shanghai Cancer Institute, Shanghai Jiao Tong University, Shanghai, China, \textsuperscript{3}Department of Gastroenterological Surgery, Peking University People’s Hospital, Beijing, China, \textsuperscript{4}Department of Gastroenterology, Shanghai Jiaotong University, Shanghai, China, \textsuperscript{5}School of Medicine, Tongji University, Shanghai, China, \textsuperscript{6}Clinical Research Management Office, Shanghai Tenth People’s Hospital, Shanghai, China

Pancreatic cancer (PC) is one of the deadliest gastrointestinal malignancies. Advances in molecular biology and surgery have significantly improved survival rates for other tumors in recent decades, but clinical outcomes for PC remained relatively unchanged. Chemodynamic therapy (CDT) and Photothermal therapy (PTT) represent an efficient and relatively safe cancer treatment modality. Here, we synthesized Mn-doped Prussian blue nanoparticles (MnPB NPs) through a simple and mild method, which have a high loading capacity for drugs and excellent CDT/PTT effect. Cell line experiments in vitro and animal experiments in vivo proved the safety of MnPB NPs. We stimulated the PC cells with MnPB NPs and performed transwell migration assays. The migration of PC cells was reduced company with the decrease of two classical proteins: matrix metalloproteinase-2 (MMP-2) and matrix metalloproteinase-9 (MMP-9). Moreover, MnPB NPs induced ferroptosis, which mediated the MAPK pathway and achieved tumor elimination in nude mice. This effective and safe strategy controlled by irradiation represents a promising strategy for pancreatic cancer.

KEYWORDS
MnPB NPs, photothermal therapy, chemodynamic therapy, pancreatic cancer, the MAPK pathway
Introduction

For a long time, the treatments of pancreatic cancer (PC) were considered limited and difficult. Because PC has an insidious onset, the opportunity for surgery is often lost when frequent clinical presentations appear. As PC incidence increases by 0.5%–1.0% per year, it is expected to become the second-leading cause of cancer-related death by 2030 (Draus et al., 2021). A few advances have been made in disease diagnosis, perioperative management, and surgical skills over the past few decades, but these advances showed limited effects on the overall survival rate (Zhao and Liu, 2020; Neoptolemos et al., 2021). Thus, novel therapeutic strategies are vital for PC treatment (Trunk et al., 2021).

Advances in nanomaterials greatly promote the development of diagnosis and treatment of cancers (Yang et al., 2012). As a novel strategy, nanoparticles make it possible to release drugs accurately, target the tumor microenvironment and kill tumor cells effectively. PTT based on photothermal material is a newly emerging therapy, which could convert light energy into heat for tumor treatment (Chang et al., 2021). Compared with other traditional therapies, there are lots of irreplaceable advantages in PTT (Sun et al., 2021; Zheng et al., 2021; Guan et al., 2022a). Firstly, PTT has no systemic damage and is particularly suitable and effective for superficial solid tumors (Wang W. et al., 2022). Moreover, PTT could be flexibly combined with other imaging examinations to kill cancer cells precisely (Xie et al., 2020). In addition, PTT has many potential advantages such as surprising efficacy in overcoming drug resistance because of the killing of cancer cells. CDT triggers Fenton and Fenton-like reactions induced by endogenous chemical energy, which kill cancer cells by generating hydroxyl radicals (·OH) (Tang et al., 2021; Zhou et al., 2021). The tumor microenvironment (TME) is typically characterized by mildly acidic conditions, defective vascular architecture, overexpression of certain enzymes, high concentrations of glutathione (GSH), and reactive oxygen species (ROS) (Li S. et al., 2020; Wang et al., 2022b). These unique properties of TME allow us to design stimuli-activatable nanoplatforms for cancer therapy. Hence, the concept of CDT has been widely used in the design of anti-tumor nanomaterials (Guan et al., 2022b). Most of these nanomaterials are inorganic transition metals containing redox activity, such as Fe(II)/Fe(III), Cu+/Cu2+, Mn2+/Mn4+ and so on. Here, we designed MnPB nanoparticles (MnPB NPs). We assumed that incorporating manganese (Mn) into Prussian blue nanoparticles (PB NPs) could improve therapy efficiency compared to PB nanoparticles alone. Besides, MnPB NPs showed the synergistic effect of PTT and CDT for PC treatment.

Ferroptosis is a novel process based on iron overloaded as well as lipid peroxidation, which has unique morphological and bioenergetic characteristics including mitochondrial shrinkage, increased mitochondrial membrane density, membrane integrity disruption, and NADH depletion (Lei et al., 2022). There has been an explosion of research about ferroptosis and PC in recent years (Kremer et al., 2021; Ye et al., 2021). PC is not responsive to most current treatment options, but targeting the ferroptosis pathway may provide an alternative. Changes in ROS are very critical to the occurrence of ferroptosis (Su et al., 2019). Using ROS generated by CDT to induce ferroptosis for cancer treatment is an attractive option. Moreover, the MAPK signaling pathway is closely related to ferroptosis. Sorafenib, a multikinase inhibitor, an agonist for ferroptosis. However, associations of the MAPK pathway and ferroptosis in nanomedicine still remain unclear.

Herein, we designed and fabricated MnPB NPs to enhance PTT/CDT for tumor therapy. In vitro and in vivo tests were conducted to determine the anti-tumor efficacy of MnPB NPs. Pancreatic cancer cells were extremely inhibited by MnPB NPs in terms of proliferation and migration. The ferroptosis regulated by the MAPK pathway was activated by MnPB NPs. These presented results indicated that MnPB NPs might contribute to a more effective therapy for pancreatic cancer treatment.

Materials and methods

Chemicals and reagents

Manganese chloride (MnCl2.4H2O), potassium ferrocyanide (K4 [Fe (CN)6]), and ethanol were purchased from Aladdin Chemistry Co. Lt. We purchased citric acid from Sigma-Aldrich. Milli-Q water was used to produce deionized water (H2O).

Preparation of MnPB NPs

Based on the co-precipitation strategy, we synthesized MnPB NPs by a simple ion-exchange method. First, 0.3 mM of MnCl2.4H2O and 0.5 mM of citric acid dissolved in 20 ml of deionized water were heated to 60°C for 5 min. As a result, solution A was formed. Solution B was formed by dissolving K4 [Fe (CN)6] (0.4 mM) and citric acid (0.4 mM) in deionized water (20 ml) and heating to 60°C under magnetic stirring for 5 min. Subsequently, we added solution B dropwise into solvent A and kept it at 60°C for 2 min. The collected product was washed with deionized water and ethanol after cooling to room temperature. In the final step, we dried the washed solution at 60°C for 24 h in a vacuum oven.

Characterization of MnPB NPs

With an acceleration voltage of 200 kV, transmission electron microscopy (TEM) observations and elemental
mapping of nanocomposites were conducted on a JEM-2100 F transmission electron microscope (TEM, JEOL, Tokyo, Japan). Crystallinity and characterization of MnPB NPs was measured using X-ray diffraction (XRD).

**Photothermal effect evaluation**

We irradiated MnPB NPs at 100, 200, and 400 μg/ml with an 808 nm near-infrared laser (1.0 W/cm²) and recorded the temperatures through an imaging camera (Fotric, Shanghai, China). Besides, we irradiated MnPB NPs solution with a NIR laser, and the solution was naturally cooled to room temperature. We calculated the photothermal conversion efficiency following the published study (Fang et al., 2021).

**Evaluation of the activity to produce ROS**

We fully mixed MnPB NPs with methylene blue (MB) solution and H₂O₂, and applied UV-vis spectroscopy to record UV–vis spectrum at varied times, which suggested the generation of ROS.

**Cell culture**

From the American Type Culture Collection (ATCC), we obtained pancreatic cancer cell line PANC-1 and normal pancreatic cell line hTERT-HPNE, and cultured according to standard ATCC protocols. Briefly, Dulbecco’s Modified Eagle medium (DMEM) containing 10% fetal bovine serum (FBS) was used to culture PANC-1 cells. The hTERT-HPNE cells were cultured as ATCC’s protocol.

**Cytotoxicity assay**

Cell viability after treatment was determined using the Cell Counting Kit-8 (CCK-8, Dojindo, Japan) assay. Cells at the density of 1500 per well were seeded in 96-well plates and incubated with MnPB NPs in a 5% CO₂ incubator for 24 h, then cells were incubated with CCK-8 solution for 90 min. Finally, the absorbance of the solution at 450 nm is measured using a microplate reader (Thermo, United States). A ratio of the absorbance of treated cells to that of control cells was used to calculate cell viability.

**ROS detection assay**

In 12-well plates, 3*10⁵ cells were plated per well and treated sequentially with Phosphate Buffered Saline (PBS), NIR, MnPB NPs, and MnPB NPs + H₂O₂. Cells were then incubated with 2’,7’-dichlorodihydrofluorescein diacetate (DCFH-DA, 10 μM) in DMEM without FBS for 20 min. The cells were washed three times with PBS, and ROS levels were measured using fluorescence microscopy (Olympus, Tokyo, Japan) afterward.

**Anticancer effect in vitro**

The Calciné-AM/propidium iodide (PI) test (Beyotime Biotechnology, Shanghai, China) were used following the instructions of manufacturers. We divided the PANC-1 cells into six groups: 1) PBS; 2) NIR; 3)H₂O₂; 4) MnPB + NIR; 5) MnPB + H₂O₂; 6) MnPB + NIR + H₂O₂. After the treatments, we stained the PANC-1 cells with Calciné-AM and PI for 20 min. Images were acquired through fluorescence microscopy (Olympus, Tokyo, Japan).

**Anticancer effect in vivo**

We suspended pancreatic cancer cells at a density of 1.0*10⁷ cells per ml in cold PBS. Four-week-old BALB/c nude mice were injected subcutaneously with 100 μl of the cell suspension containing 1*10⁶ cells. Then, the growths of tumors were monitored and measured every 3 days. Measurements of long and short diameters were used to monitor tumor growth, and the following formula was used to calculate tumor volume: V (mm³) = width² (mm²) × length (mm)/2. We divided the nude mice into four groups: 1) PBS; 2) NIR; 3) MnPB NPs; 4) MnPB NPs + NIR. In order to explore the effect of MnPB NPs, we injected 150 μl PBS into the mice of group 1 and group 2, and 150 μl MnPB NPs were injected into the mice of group 3 and group 4 intravenously. After 8 h, the mice of groups 2 and group 4 were irradiated with a laser (808 nm) for 15 min. To measure the dynamic changes of tumor temperature, a FLIR A300 thermal imaging camera was used. We monitored the tumor volume as well as body weight every 3 days. All nude mice were sacrificed after 18 days, and we conducted immunohistochemistry (Ki67) in tumor tissues, blood routine examination, liver function test, and histological analysis in five major organs.

**Colony formation assay**

Initially, 500 cells per well were seeded and cultured in six-well plates. The colonies were stained with 0.1% crystal violet (Sigma Aldrich, United States) after fixation with 4% paraformaldehyde after 2 weeks of culture. A light microscope (Olympus, Tokyo, Japan) was used to assess colonies with more than 50 cells.
Transwell migration assay

Approximately $3 \times 10^4$ cells were suspended in 200 μl of serum-free medium and seeded in an upper chamber without matrigel. About 800 μl medium with 10% FBS were added to the lower chamber in a 24-well plate. Lower chamber cells were washed, fixed, stained, and photographed after 36 h.

Western blotting

The cells were lysed in Radio Immunoprecipitation Assay (RIPA) Lysis buffer supplemented with proteases (Yesson, China) and phosphatase inhibitors (Yesson, China) for 20-min incubation on ice. The bicinchoninic acid assay kit (Yesson, China) was conducted to measure the protein concentration in cell lysates. About 8%–12% SDS-polyacrylamide gels were used to separate total protein lysates from different samples, then Polyvinylidene fluoride (PVDF) membranes were electrothermally transferred (130 V, 50 min at 4°C). The blocking solution was applied to PVDF membranes followed by incubation with specific antibodies overnight at 4°C. The following antibodies were used in this study: anti-β-actin (1: 4000, ab8227, Abcam), anti-MMP9 (1:1000, CST, Massachusetts, United States), anti-MMP2 (1:1000, CST, Massachusetts, United States), anti-MEK (1:1000, CST, Massachusetts, United States), anti-p-MEK (1:1000, CST, Massachusetts, United States), anti-p-ERK (1:1000, CST, Massachusetts, United States), anti-MEP (1:1000, CST, Massachusetts, United States), anti-ERK (1:1000, CST, Massachusetts, United States), anti-GPX4 (1:1000, CST, Massachusetts, United States).

Immunohistochemistry

Paraformaldehyde-fixed mouse subcutaneous tumor tissues were washed three times with PBS, which were then transferred into ethanol. Paraffin was used for embedding tissues. Then tissues were dewaxed and stained. The primary antibody was anti-Ki67 (1:2000, CST, Massachusetts, United States).

Statistical analysis

The statistical analysis was conducted via SPSS 22.0 statistical software and GraphPad Prism 5 (Graphpad software). There is a mean and standard deviation (SD) for all data provided. To determine the significance of the difference, Student’s t-test or one-way analysis of variance (ANOVA) was used. $p < 0.05$ was considered statistically significant. $^p < 0.05; \ ^{**}p < 0.01; \ ^{***}p < 0.001; \ ^{****}p < 0.0001; \ ns$: no significance.

Results

Construction of characterization of the MnPB NPs

The sizes and morphologies of MnPB were analyzed by TEM. The mean diameter of MnPB NPs was 237 nm (Figures 1A,B). In addition, XRD patterns showed the characteristic peaks (Figure 1C) of MnPB NPs (JCPDS No.01–0639, JCPDS No.32–0639), which suggested that MnPB NPs had been synthesized and showed the oxidation state of Mn (+2).

Photothermal property and generation of ROS

As expected, MnPB NPs exhibited broad absorption in aqueous dispersion through the NIR region (Figure 2A), which indicates MnPB NPs might be a potentially good PTT agent. Under NIR light irradiation, MnPB NPs with different concentrations were evaluated for their photothermal properties (Figure 2B). The MnPB NPs at 200 μg/ml rapidly rose to 41°C after irradiation for 10 min (Figure 2C), and the temperature could kill tumor cells irreversibly. Moreover, MnPB NPs were investigated for their photothermal conversion efficiency, which represented the ability to convert light energy into heat energy. The photothermal conversion efficiency of MnPB NPs was up to ~25.4% (Figure 2D), which was higher than other photothermal agents, such as Cu$_{2}$–Se (22% only) (Hessel et al., 2011). Thus, these data indicated that MnPB NPs were a promising PTT agent. The TME of pancreatic cancer is rich in H$_2$O$_2$ and GSH. MnPB NPs would promote the production of ROS only after entering TME. In acidic tumor microenvironment, H$_2$O$_2$ and Mn$^{2+}$ further generate OH, which could enhance effect of CDT. As showed in Figure 2E, the co-catalytic capacity of MnPB NPs was measured by MB. The characteristic absorption peak intensity at 652 nm decreased significantly over time. In addition, the absorbance of MB in presence of MnPB NPs decreased much faster than the control group (Figure 2F). These data suggested that MnPB NPs are expected to enhance CDT in the TME of pancreatic cancer.

The MnPB NPs induce intracellular ROS and cell death in PC cells

We conducted CCK-8 assays to access the biocompatibility and cytotoxicity of MnPB NPs in 2 cell lines including PANC-1 cells and hTERT-HPNE cells. MnPB NPs were incubated with both cell lines with different concentrations (0, 25, 50, 100, 200, 400 μg/ml) for 24 h. As shown in Figure 3A, the results indicated that the viabilities of both cell lines were above 80% even in the high MnPB NPs concentration incubation (400 μg/ml),
**FIGURE 1**
The characteristics of MnPB NPs (A) Low- and (B) Medium-magnification TEM image of MnPB NPs. (C) XRD spectra of MnPB NPs.

**FIGURE 2**
The photothermal properties of the MnPB NPs (A) UV-Vis-NIR absorption spectra of MnPB NPs. (B) Temperature profiles of MnPB NPs at different concentrations under laser irradiation. (C) The temperature changes of MnPB NPs (irradiation heating and natural cooling) at 200 μg/ml concentrations. (D) Linear regression for the natural cooling process. (E) Degradation of MB with the treatment of MnPB NPs and H$_2$O$_2$. (F) Absorption of MB in two groups at 664 nm.
suggesting MnPB NPs have good biocompatibility and low cytotoxicity. The CDT has attracted lots of attention based on high selectivity in tumors and fewer side effects in normal tissues during the past 5 years (Xu et al., 2021). The production of ROS is a significant part of CDT. To examine whether MnPB NPs could induce ROS, we used DCFH-DA to detect ROS in PANC-1 cells, which could transfer to 2',7'-dichlorofluorescein (DCF) under the stimulation of intracellular ROS. We observed \( \text{H}_2\text{O}_2 \) group and MnPB NPs groups showed weak increases in DCF intensity, while MnPB NPs combined with \( \text{H}_2\text{O}_2 \) group showed strong and extensive increases (Figure 3B). Calcine-AM/PI test was used to evaluate the anti-tumor efficiency of MnPB NPs. The PANC-1 cells exhibited extensive green fluorescence, as well as no red fluorescence was observed. Moreover, \( \text{H}_2\text{O}_2 \) slightly increased
the PI-positive death cells. In contrast, the PANC-1 cells treated with MnPB NPs displayed strong red fluorescence indicating remarkable cell death. There were more PI-positive cells in the group treated with MnPB NPs, NIR and H$_2$O$_2$ than in the other five groups, which demonstrated the viability of these cells was very low (Figure 3C).

The MnPB NPs inhibit PC cell migration

The process of metastasis, one of the malignant biological behaviors of tumors, involves the transduction of a series of signaling pathways and the expression of key downstream genes. To further assess whether MnPB NPs could influence the mobility of PANC-1 cells, we investigated transwell migration assays. The results certified that MnPB NPs, as well as MnPB NPs + H$_2$O$_2$, could significantly suppress the migration of PANC-1 cells (Figures 4A,B). What’s more, MMP2 and MMP9 had been reported closed related to migration and invasion of cancers (Zhao et al., 2020; Jiang and Li, 2021; Le et al., 2022). Western blotting was conducted to examine whether the treatment of MnPB NPs could decline the expression some EMT-related proteins. The results demonstrated that MMP2 and MMP9 decreased compared with the control group (Figure 4C). These results were consistent with the study published previously (Fang et al., 2022). Overall, these results indicated that MnPB NPs could inhibit migration of PANC-1 cells.

The MnPB NPs induce ferroptosis via the MAPK pathway

Multiple previous studies have demonstrated that excess ROS could lead to ferroptosis. We conducted western blotting to confirm whether MnPB NPs could induce ferroptosis in the PC cells. The results indicated that GPX4, the marker of ferroptosis, was downregulated in the group of MnPB NPs + H$_2$O$_2$ (Figure 5A), suggesting MnPB NPs induced...
FIGURE 5
The MnPB NPs promote ferroptosis in PANC-1 cells through the MAPK signal pathway. (A) The expression level of GPX4 in different treatments. (B) Cell viability was analyzed by CCK-8 assay at the indicated time in PANC-1 cells with DMSO or Ferrostain-1. (C) The colony formation assay of PANC-1 cells with DMSO or Ferrostain-1. (D) The statistical analysis of colony formation assay of PANC-1 cells with DMSO or Ferrostain-1. (E) Western blotting showed the effects of different treatments on the MAPK pathway in PANC-1 cells. (F) Cell viability was measured by CCK-8 assay at the indicated time in PANC-1 cells with DMSO or C16-PAF. (G) The colony formation assay of PANC-1 cells with DMSO or C16-PAF. (H) The statistical analysis of colony formation assay of PANC-1 cells with DMSO or C16-PAF. *p < 0.05; **p < 0.01; ***p < 0.001; ****p < 0.0001.
Ferroptosis. Moreover, Ferrostatin-1, a kind of ferroptosis inhibitor, was used for the rescue experiment. As shown in Figures 5B–D, Ferrostatin-1 enhanced the proliferation ability inhibited by MnPB NPs + H2O2. In addition, The MAPK pathway involvement in ferroptosis has been reported in previous studies. Therefore, we explored whether the MAPK pathway was responsible for the ferroptosis in PANC-1 cells induced by MnPB NPs. The results showed p-MEK and p-ERK were decreased in the group of MnPB NPs and MnPB NPs + H2O2 (Figure 5E), while total MEK 1/2 and ERK 1/2 expression displayed no change. Then we used C16-PAF to activate the MAPK signal pathway. Interestingly, we found the proliferation ability inhibited by MnPB NPs + H2O2 was markedly reversed by C16-PAF (Figures 5F–H), suggesting MnPB NPs + H2O2 mediated cell proliferation via the MAPK signal pathway. As displayed in Supplemental Figure S1, the expression of GPX4 also increased with the treatment of C16-PAF. Therefore, these data confirmed that MnPB NPs could induce ferroptosis through the MAPK pathway.

The MnPB NPs inhibit the growth of tumor in vivo

PTT combined with CDT for increasing the tumor treatment performance has aroused heated discussion. To further explore the therapeutic capacity of MnPB NPs on tumor proliferation
*in vivo*, we injected $1 \times 10^6$ PANC-1 cells into BALB/c nude mice subcutaneously. After 2 weeks, the volume of tumors reached about 100 mm$^3$. For investigating the combination of PTT and CDT to treat tumors synergistically, the mice were randomly divided into four groups ($n = 5$, per group); 1) PBS, 2) NIR, 3) MnPB NPs, 4) MnPB NPs + NIR. In group 1 and 2, we injected 200 μl PBS into mice via tail vein. For group 2, Lasers at 808 nm (1.0 W/cm$^2$) were used to irradiate. At the same time, we recorded the infrared thermal image as well as temperature. Mice of group 3 and group 4 were injected with 200 μl MnPB NPs (2 mg/ml) via the tail vein. After 12 h, the mice of group 4 were irradiated with an 808 nm NIR laser. The temperature in group 4 rapidly rose to 43.8°C after laser irradiation, which caused irreversible damage, while the temperature of mice in group 2 was less than 28°C (Figures 6A,B). After 18 days, we measured tumor volumes and weights of four groups for a reassessment of the synergistic effect of CDT and PTT. When PTT and CDT are combined in group 4, tumor ablation was significantly increased compared to the other three groups (Figures 6C–E). Next, we applied IHC to evaluate the proliferation status of PC cells, the results indicated that MnPB NPs with NIR could significantly inhibit the growth of PC (Figure 6F).
**In vivo biosafety of MnPB NPs**

Biosafety is very significant for biomaterials application. Therefore, blood routine examination, and liver function test were carried out for blood/liver damage evaluations. The results demonstrated there were few differences among all groups (Figures 7A–G), indicating the treatment of MnPB NPs was safe. Moreover, we conducted HE staining of four groups. The results showed that NIR, MnPB NPs, and MnPB NPs + NIR groups had obscure adverse effects in various organs compared with the PBS group (Figure 7H). In summary, good biosafety of MnPB NPs is guaranteed.

**Discussion**

Pancreatic cancer is a well-known deadly disease with similar mortality and morbidity, and its incidence continues to increase, while 5-years relative survival remains the lowest (9%) in all cancers (Chen et al., 2021; Tonini and Zanni, 2021). Furthermore, most pancreatic cancer patients undergo recurrence and metastasis. Despite advances in surgical approaches, its poor prognosis has not improved over the past few decades (Cai et al., 2021). More research is needed to explore and develop new treatments. PB NPs have been widely used in biomedical fields, including staining in histological experiments and targeted drug delivery in cancers, due to their advantages of biocompatibility, affordable production cost, and easy synthesis, which suggests these unique properties make PB NPs potential candidates for a variety of medical applications (Butler and Sadler, 2013; Gautam et al., 2018; Qin et al., 2018). PB NPs exhibit excellent phototherapeutic effects because they have a wide absorption range (500–900 nm) in the near infrared (NIR) region. The FDA has approved PB NPs for the treatment of diseases caused by radiation exposure (Sheikh et al., 2012; Aaseth et al., 2019). Moreover, researchers have identified PB NPs as new photothermal conversion agents for cancer treatment using NIR (Patra, 2016; Haque and Patra, 2021). However, the efficiency of PTT alone is limited because it cannot completely inhibit the tumor. Therefore, combining other metal ions with PB NPs to amplify the advantages of PTT or CDT is expected to become a promising cancer treatment strategy in the future (Wen et al., 2022). In this study, we added an appropriate amount of manganese ions into PB NPs to construct a novel nanoparticle for pancreatic cancer treatment. The keys to PTT are photothermal agents. When photothermal agents are irradiated by the light of an appropriate wavelength, they absorb photon energy and interaction occurred between stimulated molecules and surrounding molecules. This interaction leads to the production of heat, which in turn kills tumor cells. To confirm that MnPB NPs are reliable, several experiments were conducted in this study. Firstly, we evaluated the biosafety of MnPB NPs through the CCK-8 assay. The results showed that MnPB NPs had not much effect on pancreatic cancer cells as well as normal pancreatic cells even if the concentration was up to 400 μg/ml. Moreover, biosafety experiments in vivo also confirmed that the MnPB NPs did not cause damage to five major organs. MnPB NPs have a lethal effect on pancreatic cancer cells under near-infrared irradiation. In addition, the results of animal experiments showed the same conclusion, and the adjacent normal tissues were not affected. Briefly, MnPB NPs dissolve manganese ion and activate the Fenton reaction in the TME. Under the catalysis of MnPB NPs, the reaction is as follows:

\[
\begin{align*}
\text{Fe}^{2+} + \text{H}_2\text{O}_2 & \rightarrow \text{Fe}^{3+} + \cdot \text{OH} + \text{OH}^- \\
\text{H}_2\text{O}_2 + \text{Mn}^{2+} & \rightarrow \text{Mn}^{3+} + \cdot \text{OH} + \text{OH}^- 
\end{align*}
\]

On the one hand, CDT produced excessive ·OH, which would oxidize many important cellular components including DNA, proteins, and lipids. Excessive oxidation could lead to irreversible cell death, especially ferroptosis (Li et al., 2020). On the other hand, to some extent, the O₂ catalyzed by MnPB NPs could alleviate tumor hypoxia, which was regarded as the key to drug resistance and tumor metastasis (Harris, 2002; Popper, 2016; Jing et al., 2019). Hence, MnPB NPs are of great significance in the treatment of PC, which could bring Fenton reaction. DCFH-DA fluorescence intensity measurement showed that MnPB NPs significantly upregulated the ROS level of PANC-1 cells under H2O2 conditions. In addition, we speculated that the cell death caused by MnPB NPs was ferroptosis induced by excessive ROS. Then the change of GPX4, the marker of ferroptosis, was examined by western blotting in four groups. The results indicated ferroptosis in PANC-1 cells was caused by MnPB NPs.

We further explored the mechanism of ferroptosis that occurred in tumor cells. Previous studies revealed that ferroptosis was regulated by some signal pathways. The MAPK pathway plays a crucial role in ferroptosis (Wang et al., 2022c; Ko et al., 2022; Ma et al., 2022). It is reported that the activation of the MAPK pathway is necessary for the ferroptosis of PC cells. Here, western blotting was conducted to confirm the MAPK pathway was suppressed by MnPB NPs. Besides, the phenotype of PANC-1 cells was rescued by C16-PAF, a kind of MAPK pathway activator. Interestingly, the expression of GPX4 was also upregulated by C16-PAF. Therefore, we declared that ferroptosis was regulated by MAPK pathway in PANC-1 cells.

**Conclusion**

We synthesized MnPB NPs following a stepwise reaction method. MnPB NPs have satisfactory biocompatibility in vivo and in vitro. Moreover, MnPB NPs have great potential in synergistic treatments of CDT and PTT, which could produce strong anti-tumor effects, especially inhibiting tumor proliferation.
and metastasis efficiently. The anti-tumor functions were mediated by the MAPK pathway. Our research indicated the potential of MnPB NPs to develop a new therapeutic strategy for PC. However, more detailed safety and pharmacokinetics studies should be conducted to bring further applications to the clinic.

Data availability statement

The original contributions presented in the study are included in the article/Supplementary Material, further inquiries can be directed to the corresponding authors.

Ethics statement

The animal study was reviewed and approved by the ethics committee of Shanghai 10th People's Hospital (approval number: SHDSYY-2022–4413).

Author contributions

ST, ZY, FY carried out the experiments (qPCR, western blotting, immunohistochemistry, cell culture and cell functional assays) and analyzed data. QY, JC, LH carried out the animal experiments. WG and MQ designed experiments, supervised the study and polished the manuscript. All authors read and approved the final manuscript.

References

Aaseth, J., Nurchi, V. M., and Andersen, O. (2019). Medical therapy of patients contaminated with radioactive cesium or iodine. Biomolecules 9, 856. doi:10.3390/biom9120856
Butler, J. S., and Sadler, P. J. (2013). Targeted delivery of platinum-based anticancer complexes. Curr. Opin. Chem. Biol. 17, 173–188. doi:10.1016/j.cobrep.2013.01.004
Cai, J., Chen, H., Lu, M., Zhang, Y., Lu, B., You, L., et al. (2021). Advances in the epidemiology of pancreatic cancer: Trends, risk factors, screening, and prognosis. Cancer Lett. 528, 1–11. doi:10.1016/j.canlet.2021.06.027
Chang, M., Hou, Z., Wang, M., Li, C., and Lin, J. (2021). Recent advances in hyperthermia therapy-based synergistic immunotherapy. Adv. Mat. 33, e2004788. doi:10.1002/adma.202004788
Chen, X., Zeh, H. J., Kang, R., Kroemer, G., and Tang, D. (2021). Cell death in pancreatic cancer. From pathogenesis to therapy. Nat. Rev. Gastroenterol. Hepatol. 18, 804–823. doi:10.1038/s41575-021-00486-6
Draus, T., Ansari, D., Wikstrom, F., Persson, U., and Andersson, R. (2021). Projected economic burden of pancreatic cancer in Sweden in 2030. Acta Oncol. 60, 866–871. doi:10.1080/02841079.2021.1892821
Fang, D., Jin, H., Huang, X., Shi, Y., Liu, Z., and Ben, S. (2021). PPy@ Fe3O4 nanoparticles inhibit tumor growth and metastasis through chemodynamic and photothermal therapy in non-small cell lung cancer. Front. Chem. 9, 789934. doi:10.3389/fchem.2021.789934
Fang, D., Liu, Z., Jin, H., Huang, X., Shi, Y., and Ben, S. (2022). Manganese-based prussian blue nanocatalysts suppress non-small cell lung cancer growth and metastasis via photothermal and chemodynamic therapy. Front. Bioeng. Biotechnol. 10, 939158. doi:10.3389/fbioe.2022.939158
Gautam, M., Poudel, K., Yong, C. S., and Kim, J. O. (2018). Prussian blue nanoparticles: Synthesis, surface modification, and application in cancer treatment. Int. J. Pharm. 549, 31–49. doi:10.1016/j.ijpharm.2018.07.055
Guan, S., Liu, X., Fu, Y., Li, C., Wang, J., Mei, Q., et al. (2022a). A biodegradable "Nano-donut" for magnetic resonance imaging and enhanced chemo/photothermal/chemodynamic therapy through responsive catalysis in tumor microenvironment. I. Colloid Interface Sci. 608, 344–354. doi:10.1016/j.jcis.2021.09.186
Guan, S., Liu, X., Li, C., Wang, X., Cao, D., Wang, Y., et al. (2022b). Intracellular mutual amplification of oxidative stress and inhibition multidrug resistance for enhanced sonodynamic/chemodynamic/chemo therapy. Small 18, e2107160. doi:10.1002/smll.202107160
Haque, S., and Patra, C. R. (2021). Silver Prussian blue analogue nanomedicine for future cancer therapy. Future Oncol. 17, 119–122. doi:10.2217/fon-2020-0736
Harris, A. L. (2002). Hypoxia—a key regulatory factor in tumour growth. Nat. Rev. Cancer 2, 38–47. doi:10.1038/nrc2470
Hessel, C. M., Pattani, V. P., Rasch, M., Panthani, M. G., Koo, B., Tunnell, J. W., et al. (2011). Copper selenide nanocrystals for photothermal therapy. Nano Lett. 11, 2560–2566. doi:10.1021/nl201400z
Jiang, H., and Li, H. (2021). Prognostic values of tumoral MMP2 and MMP9 overexpression in breast cancer: A systematic review and meta-analysis. BMC Cancer 21, 149. doi:10.1186/s12885-021-07860-2
Jing, X., Yang, F., Shao, C., Wei, K., Xie, M., Shen, H., et al. (2019). Role of hypoxia in cancer therapy by regulating the tumor microenvironment. Mol. Cancer 18, 157. doi:10.1186/s12943-019-1089-9
Ko, J., Jang, S., Kwon, W., Kim, S. Y., Jang, S., Kim, E., et al. (2022). Protective effect of GIP against monosodium glutamate-induced ferrotosis in mouse

Funding

This study was supported by the Cultivation project of National Natural Science Foundation of China (2021GZRYNPY29).

Conflict of interest

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Publisher’s note

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

Supplementary material

The Supplementary Material for this article can be found online at: https://www.frontiersin.org/articles/10.3389/fchem.2022.1026924/full#supplementary-material
hippocampal HT-22 cells through the MAPK signaling pathway. *Antioxidants* (Basel) 11, 1189. doi:10.3390/antiox11020189

Kremer, D. M., Nelson, B. S., Lin, L., Yarosz, E. L., Halbrook, C. J., Kerk, S. A., et al. (2021). GOT1 inhibition promotes pancreatic cancer cell death by ferroptosis. *Nat. Commun.* 12, 4860. doi:10.1038/s41467-021-24859-2

Le, T. C., Polat, S., Lee, J., Kim, G. J., Kim, H., Lee, E. Y., et al. (2022). Marine desipreotide nobilamide I inhibits cancer cell motility and tumorigenicity via suppressing epithelial-mesenchymal transition and MMP2/9 expression. *ACS Omega* 7, 1722–1732. doi:10.1021/acsomega.1c04520

Lei, G., Zhuang, L., and Gao, B. (2022). Targeting ferroptosis as a vulnerability in cancer. *Nat. Rev. Cancer* 22, 381–396. doi:10.1038/s41566-022-00459-0

Li, J., Cao, F., Yin, H. L., Huang, Z. J., Lin, Z. T., Mao, N., et al. (2020a). Ferroptosis: Past, present and future. *Cell Death Dis.* 11, 88. doi:10.1038/s41419-020-2298-2

Li, S., Zhang, W., Xue, H., Xing, R., and Yan, X. (2020b). Tumor microenvironment-oriented adaptive nanodrugs based on peptide self-assembly. *Chem. Sci.* 11, 8644–8656. doi:10.1039/d0sc02937h

Ma, X., Yan, W., and He, N. (2022). Lidocaine attenuates hypoxia/reoxygenation-induced inflammation, apoptosis and ferroptosis in lung epithelial cells by regulating the p38 MAPK pathway. *Mol. Med. Rep.* 25, 150. doi:10.3892/mmr.2022.12666

Neoptolemos, J. P., Springer, C., and Hackert, T. (2021). A review of pancreatic cancer. *JAMA* 326, 2436. doi:10.1001/jama.2021.20065

Patra, C. R. (2016). Prussian blue nanoparticles and their analogues for application to cancer theranostics. *Nanomedicine (Lond)* 11, 569–572. doi:10.2116/nmm.16-16

Popper, H. H. (2016). Progression and metastasis of lung cancer. *Cancer Metastasis Rev.* 35, 75–91. doi:10.1007/s10555-015-9618-0

Qin, Z., Li, Y., and Gu, N. (2018). Progress in applications of prussian blue nanoparticles in biomedicine. *Adv. Healthc. Mat.* 1–10. doi:10.1002/adhm.201800347

Sheikh, S., McCormick, L. C., Pevear, J., Adoff, S., Walter, F. G., and Kazzi, Z. N. (2020). Reactive oxygen species-induced lipid peroxidation in apoptosis, autophagy, and ferroptosis: Past, present and future. *Frontiers in Chemistry* frontiersin.org

Trunk, A., Miotke, L., Nevala-Plagemann, C., Verdaguer, H., Macarulla, T., and Garrido-Laguna, I. (2021). Emerging treatment strategies in pancreatic cancer. *Pancreas* 50, 773–787. doi:10.1097/MPA.0000000000001845

Wang, W., Zhang, X., Ni, X., Zhou, W., Xie, C., Huang, W., et al. (2022a). Semiconducting polymer nanoparticles for NIR-II fluorescence imaging-guided photothermal/thermodynamic combination therapy. *Biomater. Sci.* 10, 846–853. doi:10.1039/d1bm01464d

Wang, X., Li, C., Jin, H., Wang, X., Ding, C., Cao, D., et al. (2022b). Mutual promotion of oxidative stress amplification and calcium overload by degradable spatially selective self-cascade catalyst for synergistic tumor therapy. *Chem. Eng. J.* 432, 134438. doi:10.1016/j.cej.2021.134438

Wang, X., Zhang, C., Zou, N., Chen, Q., Wang, C., Zhou, X., et al. (2022c). Lipocalin-2 silencing suppresses inflammation and oxidative stress of acute respiratory distress syndrome by ferroptosis via inhibition of MAPK/ERK pathway in neonatal mice. *Bioengineering* 13, 508–520. doi:10.3390/bioengineering13020050

Wang, W., Zhang, X., Guo, X., Cao, Z., Meng, N., Shen, X. C., et al. (2022). NIR-II-responsive AuNRs@SiO2-RB@MnO2 nanotheranostic for multimodal imaging-guided CD47/PDT synergistic cancer therapy. *J. Mat. Chem. B* 10, 4274–4284. doi:10.1039/d1tb02807h

Xie, C., Zhou, W., Zeng, Z., Fan, Q., and Pu, K. (2020). Grafted semiconducting polymer amphiphiles for multimodal optical imaging and combination phototherapy. *Chem. Sci.* 11, 10553–10570. doi:10.1039/d0sc01712c

Xu, L., Xu, R., Saw, P. E., Wu, J., Cheng, S. X., and Xu, X. (2021). Nanoparticle-mediated inhibition of mitochondrial glutaminolysis to amplify oxidative stress for combination cancer therapy. *Nano Lett.* 21, 7569–7578. doi:10.1021/acs.nanolett.1c02073

Yang, F., Jin, C., Subedi, S., Lee, C. L., Wang, Q., Jiang, Y., et al. (2012). Emerging inorganic nanomaterials for pancreatic cancer diagnosis and treatment. *Cancer Treat. Rev.* 38, 566–579. doi:10.1016/j.ctrrev.2012.02.003

Ye, Z., Zhao, Q., Hu, Q., Xu, X., Mengli, L., Zhang, Z., et al. (2021). FBW7-NRA41-SCD1 axis synchronously regulates apoptosis and ferroptosis in pancreatic cancer cells. *Redox Biol.* 38, 101807. doi:10.1016/j.redox.2020.101807

Zhao, M. Y., Zhao, T., Meng, Q. Y., Zhao, L., and Li, X. C. (2020). Estrogen and estrogen receptor affects MMP2 and MMP9 expression through classical ER pathway and promotes migration of lower venous vascular smooth muscle cells. *Eur. Rev. Med. Pharmacol. Sci.* 24, 1460–1467. doi:10.26355/eurrev_202002_20205

Zhao, Z., and Liu, W. (2020). Pancreatic cancer: A review of risk factors, diagnosis, and treatment. *Technol. Cancer Res. Treat.* 19, 15330338209621. doi:10.1177/1533033820962117

Zheng, N., Wang, Q., Li, C., Wang, X., Liu, X., Wang, X., et al. (2021). Responsive degradable theranostic agents enable controlled selenium delivery to enhance photothermal radiotreatment and reduce side effects. *Adv. Healthc. Mat.* 10, e2002024. doi:10.1002/adhm.202002024

Zhou, Y., Fan, S., Feng, L., Huang, X., and Chen, X. (2021). Manipulating intratumoral Fenton Chemistry for enhanced chemodynamic and chemodynamic synergized multimodal therapy. *Adv. Mat.* 33, e2104223. doi:10.1002/adma.202104223